Tag: Trastuzumab
Biocon Biologics partners Sandoz Australia for sale of biosimilars, Trastuzumab &...
The agreement is effective from January 1, 2024 and commercialization commenced on February 1, 2024
AstraZeneca India launches Trastuzumab deruxtecan for HER-2 positive metastatic breast cancer...
Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate
Biocon & Mylan’s biosimilar ‘Trastuzumab’ gets approval from Brazilian regulator
Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2positive metastatic breast cancer. The product will be marketed by the Libbs Farmaceutica........
US-FDA accepts Mylan & Biocon’s joint application on biosimilar Trastuzumab
While the Biologics License Application (BLA) for MYL-1401O has been accepted by the United States FDA, if approved, it has the potential to be the first biosimilar Trastuzumab in the US....
Mylan & Biocon announce first joint USFDA submission for biosimilar, Trastuzumab
Besides being an important milestone of Biocon and Mylan's joint global biosimilars program, the first biosimilar trastuzumab if approved by the top regulator.....